

MEDICAL ONCOLOGY

PAPER – III

Time : 3 hours

MED.ONCO./D/17/17/III

Max. Marks : 100

Important instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. a. What is metronomics in cancer care? 2+3+5
b. Mechanisms proposed for metronomic therapy.
c. Mention randomized trial based inference for and against use of metronomic therapy in refractory cancers.
2. With respect to oral cancer, describe: 3+3+4
a. Epidemiology
b. Role of viral etiology
c. Role of targeted therapy
3. a. Epidemiology of gall bladder cancer in India 4+3+3
b. Staging of gall bladder cancer.
c. Role of chemotherapy in unresectable gall bladder cancer
4. a. Diagnosis of pontine glioma 4+6
b. Medical management of pontine glioma including targeted therapy
5. a. What are the domains of quality of life assessment? 5+5
b. Mention the tools for assessment of quality of life.
6. a. Predictors of graft versus host disease in haploidentical transplant 4+6
b. Pros and cons of cord stem cell transplant versus haploidentical transplant for malignancies.
7. a. How is a biosimilar molecule different from a generic molecule? 4+3+3
b. What are the trial requirement for a biosimilar agent in India?
c. What is a phase IV clinical trial? **P.T.O.**

MEDICAL ONCOLOGY

PAPER – III

8. a. Which cases of breast and ovarian cancer you would send for genetic counseling? 3+2+2+3
b. What diagnostic tests would be performed for detecting hereditary breast / ovarian cancer syndrome?
c. How would you plan the follow up of these patients?
d. What is the supporting evidence for prophylactic mastectomy in this setting?
9. a. Staging system of neuroblastoma. 4+3+3
b. How is stage IVS neuroblastoma different from stage IV neuroblastoma.
c. Targeted therapy for neuroblastoma.
10. a. Role of viral and bacterial infections in causing lymphoma. 4+3+3
b. Treatment of an organism related lymphoma- Explain with example.
c. Setting of lymphoma where only radiotherapy is used.
